醫脈通(02192.HK)斥3,393萬人民幣收購翎博市場信息諮詢60%股權
醫脈通(02192.HK)宣佈,全資附屬金葉天成北京與三名賣方訂立股權轉讓協議,將以代價3,393萬元人民幣,收購翎博市場信息諮詢(上海)有限公司的60%股權。
目標公司主要從事爲藥企提供調研服務的業務。協議中列明利潤保證條款,金葉天成北京將獲授予選擇權,若翎博市場信息於截至2023年、2024年、2025年及2026年12月31日止四個財政年度,累計經審覈淨利潤未達到保證利潤2,172萬元人民幣的50%,則金葉天成北京有權但無義務要求賣方購回是次轉讓的60%股權。
醫脈通預期,收購博市場信息諮詢後可與公司業務資源相互結合,爲藥企客戶提供升級的調研產品和服務,進一步豐富旗下整合營銷產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.